Date:11/19/2012

trategic Alliance Focused Primarily on Metabolic Diseases.  In August 2012, Regulus entered into a strategic alliance with AstraZeneca AB ("AZ") to discover, develop, and commercialize microRNA therapeutics for three exclusive targets focused on cardiovascular and metabolic diseases and oncology.  AZ made an upfront payment of $3.0 million and purchased $25.0 million of Regulus' common stock in a private placement that closed concurrently with the IPO. In addition, Regulus is eligible to receive preclinical, clinical and commercialization milestone payments of up to $509.0 million, as well as royalties. 

Established Research Collaboration to Explore microRNA Biomarkers for Multiple Sclerosis.  In August 2012, Regulus formed a collaboration with Biogen Idec Inc. ("Biogen Idec") to explore microRNA biomarkers for multiple sclerosis.  Regulus received an upfront payment of $750,000 and is eligible to receive milestone payments of up to $1.3 million.  Regulus also received $5.0 million from the sale of a convertible note to Biogen Idec which converted into shares of Regulus' common stock at the closing of the IPO. 

Re-Aligned Board of Directors.  In November 2012, Douglas E. Williams, Ph.D., Executive Vice President of Research and Development at Biogen Idec, joined Regulus' Board of Directors.  Concurrently, Stanley T. Crooke, M.D., Ph.D., Chairman of the Board and CEO of Isis Pharmaceuticals, Inc., and Barry E. Greene, President and Chief Operating Officer of Alnylam Pharmaceuticals, Inc., stepped down from the Board and their respective Board committees. 

Third Quarter 2012 Financial Results & HighlightsAs of September 30, 2012, Regulus had cash, cash equivalents and short-term investments of $30.9 million compared to $38.1 million at December 31, 2011.  The decrease in cash, cash equivalents and short-term investments was the result of approximately $17.7 m
'/>"/>

SOURCE Regulus Therapeutics Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
2. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
3. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
4. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
5. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
6. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
7. Grupo Casa Saba Reports - Grupo Casa Saba Announces its Intention to Delist From the New York Stock Exchange
8. Solos Endoscopy Reports Book Value of $2,393,522 for Period Ended September 30, 2012
9. ULURU Inc. Reports Third Quarter 2012 Financial Results
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
11. China Pharma Holdings, Inc. Reports Third Quarter 2012 Financial Results